LALANI, A.-K. A.; LI, H.; HENG, D. Y.; WOOD, L.; KALIRAI, A.; BJARNASON, G. A.; SIM, H.-W.; KOLLMANNSBERGER, C. K.; KAPOOR, A.; HOTTE, S. J.; VANHUYSE, M.; CZAYKOWSKI, P.; REAUME, M. N.; SOULIERES, D.; VENNER, P.; NORTH, S.; BASAPPA, N. S. First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. Canadian Urological Association Journal, [S. l.], v. 11, n. 3-4, p. 112–7, 2017. DOI: 10.5489/cuaj.4398. Disponível em: https://cuaj.ca/index.php/journal/article/view/4398. Acesso em: 23 apr. 2024.